News und Analysen
Waters’ New Battery Cycler Microcalorimeter Solution Accelerates Real-World Testing from Months to Weeks
PITTCON 2023 — Waters Corporation (NYSE:WAT) today announced a new Battery Cycler Microcalorimeter Solution from its TA Instruments™ Division for high-resolution characterization of battery cells
Waters Introduces Next-Generation Alliance iS HPLC System Aimed at Reducing Up to 40% of Common Lab Errors
PITTCON 2023 – Waters Corporation (NYSE:WAT) today introduced Alliance iS, the next-generation intelligent HPLC System, designed to reduce compliance risk by adding new levels of proactive error
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
AEVIS VICTORIA SA – Consolidated EBITDA 2022 up by more than 60% to between CHF 125 and 130 million (2021: CHF 78.4m); net profit 2022 will exceed CHF 60 million (2021: CHF 4.6m)
EQS-News: Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: Newron to present at the 31st European Congress of Psychiatry
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS
EQS-News: Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-Adhoc: GN Store Nord A/S: Update on the agenda for GN Store Nord’s Annual General Meeting and capital raise
GenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314006021/en/
Figure 1: Global evolution of mean BCVA over two
EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer
Geisinger and Acadia Healthcare Appoint Kelly Ankenbrand as CEO of Geisinger Behavioral Health Center Northeast
Geisinger and Acadia Healthcare have named Kelly Ankenbrand, M.B.A., as chief executive officer for Geisinger Behavioral Health Center Northeast, a new 96-bed inpatient behavioral health hospital
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: Biotest AG: Biotest donates human albumin for earthquake victims in Turkey
EQS-News: Newron announces 2022 financial results and provides outlook for 2023
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230312005028/en/
Graph 1: Evolution of Best-Corrected Visual Acuity
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
LivaNova erhält 510(k)-Freigabe der US-amerikanischen FDA für Essenz-Herz-Lungen-Maschine für kardiopulmonale Bypassverfahren
LivaNova PLC (Nasdaq: LIVN), ein marktführendes Unternehmen im Bereich medizintechnische Innovationen, gab heute bekannt, dass es die 510(k)-Freigabe von der US-amerikanischen Food and Drug
LivaNova Receives U.S. FDA 510(k) Clearance for Essenz Heart-Lung Machine for Cardiopulmonary Bypass Procedures
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Essenz™
EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023